Dr. John Cush RheumNow
3 years 3 months ago
Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS
- it works but is it different from existing IL-17i?
- appears to work well in TNFi-inadequate responders
- are TNFi-IR pts immunologically different?
#RNL2023 https://t.co/bHboX3Xz6M https://t.co/kCa9MbFdxs
Dr. John Cush RheumNow
3 years 3 months ago
A short review from Dr. Deodhar for axSpA at #RNL2023
*prevalence is increasing
*remember the "3,4,5 rule" for MRI eval
*IL17 appear to be as good as TNFi
*may not need XR monitoring
*time will tell if IL17Fi will improve outcomes
https://t.co/fNhZZBmgaS https://t.co/g0g7e3Napl
A study of adults aged 45-85 yrs shows that knee osteoarthritis (OA) is an independent risk factor for falls, suggesting a greater need for awareness and prevention.
Data were derived from a 3 year Canadian Longitudinal (Survey) Study on Aging examing those with reported knee OA or no arthritis at baseline (n=21,710).
Overall, those with knee OA, 10%, reported one or more injurious falls (6% 1 fall, 4% 2+ falls).
Dr. John Cush RheumNow
3 years 3 months ago
ICYMI: Spondyloarthritis Innovations
https://t.co/N7AHcRIwcG https://t.co/eAgdiGTawz
Multinational metanalyses of data between 1989 and 2022 shows that NSAID prescriptions have decreased over time, and differs according to geographical locations.
Dr. John Cush RheumNow
3 years 3 months ago
Therapeutic Plasma Exchange: Core Curriculum 2023 - Comprehensive, full read overview from American Journal of Kidney diseases & the National Kidney Foundation https://t.co/rmwwj5gol3 https://t.co/XFRZyD6hV4
Dr. John Cush RheumNow
3 years 3 months ago
View our infographic from the #LupusEducatorsNetwork and discover how you can apply the concept of #DiseaseModification in #Lupus and #LupusNephritis to help treat patients in your clinical practice #SponsoredbyGSKUSMA
https://t.co/fzspfwarK4 https://t.co/jXNte7f0sY
Dr. John Cush RheumNow
3 years 3 months ago
Watch: RNL23 Vasculitis Faculty Panel Q&A
RheumNow Live 2023: Robert Spiera, MD, Hospital for Special Surgery Anisha Dua, MD, MPH, Northwestern University, Feinberg School of Medicine Carol Langford, MD, MHS, FACP
https://t.co/4ddqt2tAQ8 https://t.co/KIPp3rePpp
Dr. John Cush RheumNow
3 years 3 months ago
SURPASS: SEC vs ADA for axSpA
Outcome: %pts with no radiographic progression
Not benefit- Secukinumab not better than adalimumab
Though negative study, in all groups the progression was very low (<1 mSASS) - both interventions did well! #RNL2023 https://t.co/xlw4nzrwpm https://t.co/dhhLMFQnhI
Dr. John Cush RheumNow
3 years 3 months ago
Watch: GPA Treatment Choices
https://t.co/MU6gZrgYDr https://t.co/lT1jI9jGGS
Dr. John Cush RheumNow
3 years 3 months ago
Colchicine does not work in Hand OA. Danish trial of 100 HOA pts (age 71 yrs) given placebo or COL 0.5 mg bid x 12wk. Finger pain improved –13·9 mm w/ colchicine vs –13·5 mm w/ PBO (NS). More adverse events w/ Colchicine (72% vs 44%) https://t.co/rfANCLcZii https://t.co/OFuMGZSvhm
Dr. John Cush RheumNow
3 years 3 months ago
Risk factors for radiographic progression:
Men ♂️
Smoking 🚬
Active inflammation🔥
Blue collar workers 💪
HLA-B27+ 💉
Pre-existing syndesmophyte 🩻
Atul Deodhar at #RNL2023 @RheumNow https://t.co/FcwrDtOG6I https://t.co/AvRpPrg1UK
Dr. John Cush RheumNow
3 years 3 months ago
BIOBADASER registry of 3,366 RA/AS/PsA pts on 1,2 bDMARDs saw Remission-related Biologic D/C by 80 pts (2.4%). D/C Factors: short Dz duration (OR: 0.95), no csDMARDs (OR:0.56), shorter use prior bDMARD. Less D/C w/ smoking & ACPA+ https://t.co/iUdU9iI4AZ https://t.co/TknRW6pnJR
Dr. John Cush RheumNow
3 years 3 months ago
INBUILD study was an all cause ILD nintedanib RCT (n=663). Subanalysis of 89 RA-ILD pts showed FVC decline (@ 52 wks) was −82.6 mL/yr on NIN vs −199.3 mL/yr on PBO (p=.037). NIN diarrhea in 62%; & AE discontinuation in 24% https://t.co/nWuGx6wjB2 https://t.co/LVwy1Z5TL3
